JP2020147571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020147571A5 JP2020147571A5 JP2020084527A JP2020084527A JP2020147571A5 JP 2020147571 A5 JP2020147571 A5 JP 2020147571A5 JP 2020084527 A JP2020084527 A JP 2020084527A JP 2020084527 A JP2020084527 A JP 2020084527A JP 2020147571 A5 JP2020147571 A5 JP 2020147571A5
- Authority
- JP
- Japan
- Prior art keywords
- trifluoromethyl
- amino
- pyridin
- pyridine
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- SWWHCQCMVCPLEQ-UHFFFAOYSA-N propan-2-yl methanesulfonate Chemical compound CC(C)OS(C)(=O)=O SWWHCQCMVCPLEQ-UHFFFAOYSA-N 0.000 claims 3
- -1 4- [6- (trifluoromethyl) pyridin-2-yl] -6-{[2- (trifluoromethyl) pyridin-4-yl] amino} -1,3,5-triazine-2-yl Chemical group 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- URUBZXVIOILFLM-UHFFFAOYSA-N CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O Chemical compound CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O URUBZXVIOILFLM-UHFFFAOYSA-N 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056996P | 2014-09-29 | 2014-09-29 | |
| US62/056,996 | 2014-09-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516874A Division JP2017529382A (ja) | 2014-09-29 | 2015-09-28 | 治療活性を有する化合物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020147571A JP2020147571A (ja) | 2020-09-17 |
| JP2020147571A5 true JP2020147571A5 (enExample) | 2021-01-28 |
Family
ID=54289133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516874A Pending JP2017529382A (ja) | 2014-09-29 | 2015-09-28 | 治療活性を有する化合物及びその使用方法 |
| JP2020084527A Pending JP2020147571A (ja) | 2014-09-29 | 2020-05-13 | 治療活性を有する化合物及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516874A Pending JP2017529382A (ja) | 2014-09-29 | 2015-09-28 | 治療活性を有する化合物及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9694013B2 (enExample) |
| EP (1) | EP3200800A1 (enExample) |
| JP (2) | JP2017529382A (enExample) |
| KR (1) | KR20170057411A (enExample) |
| AU (1) | AU2015324158A1 (enExample) |
| CA (1) | CA2962943A1 (enExample) |
| IL (1) | IL251246A0 (enExample) |
| WO (1) | WO2016053850A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI666208B (zh) * | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| WO2016053850A1 (en) * | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| KR102628370B1 (ko) * | 2015-02-04 | 2024-01-24 | 르 라보레또레 쎄르비에르 | 치료적 활성 화합물 및 이들의 사용 방법 |
| US9751863B2 (en) | 2015-08-05 | 2017-09-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| SG10201912886XA (en) | 2015-10-15 | 2020-02-27 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| SG10201912869WA (en) | 2015-10-15 | 2020-02-27 | Celgene Corp | Combination therapy for treating malignancies |
| MX380596B (es) | 2015-12-04 | 2025-03-12 | Agios Pharmaceuticals Inc | Compuesto para usarse en el tratamiento de neoplasias malignas. |
| EP3419593B1 (en) | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
| WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
| CN109715143A (zh) * | 2016-09-07 | 2019-05-03 | 细胞基因公司 | 片剂组合物 |
| ES2968376T3 (es) | 2017-05-05 | 2024-05-09 | Memorial Sloan Kettering Cancer Center | Métodos de tratamiento de neoplasia mieloproliferativa |
| WO2019078246A1 (ja) * | 2017-10-19 | 2019-04-25 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| EP3716972A4 (en) * | 2017-11-29 | 2021-08-25 | The Rockefeller University | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020239759A1 (en) * | 2019-05-27 | 2020-12-03 | Sandoz Ag | Amorphous enasidenib in a stabilized form |
| JP2023503842A (ja) * | 2019-11-14 | 2023-02-01 | セルジーン コーポレーション | がんを処置するための小児用製剤 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201403878QA (en) | 2012-01-06 | 2014-08-28 | Agios Pharmaceuticals Inc | Therapeutically active compounds and their methods of use |
| NZ715738A (en) | 2013-07-11 | 2021-06-25 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| WO2016053850A1 (en) | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| KR102628370B1 (ko) | 2015-02-04 | 2024-01-24 | 르 라보레또레 쎄르비에르 | 치료적 활성 화합물 및 이들의 사용 방법 |
| US9751863B2 (en) | 2015-08-05 | 2017-09-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| SG10201912886XA (en) | 2015-10-15 | 2020-02-27 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| MX380596B (es) | 2015-12-04 | 2025-03-12 | Agios Pharmaceuticals Inc | Compuesto para usarse en el tratamiento de neoplasias malignas. |
| EP3419593B1 (en) | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
-
2015
- 2015-09-28 WO PCT/US2015/052598 patent/WO2016053850A1/en not_active Ceased
- 2015-09-28 US US14/868,283 patent/US9694013B2/en active Active
- 2015-09-28 JP JP2017516874A patent/JP2017529382A/ja active Pending
- 2015-09-28 AU AU2015324158A patent/AU2015324158A1/en not_active Abandoned
- 2015-09-28 EP EP15778158.4A patent/EP3200800A1/en not_active Withdrawn
- 2015-09-28 KR KR1020177010757A patent/KR20170057411A/ko not_active Ceased
- 2015-09-28 CA CA2962943A patent/CA2962943A1/en not_active Abandoned
-
2017
- 2017-03-17 IL IL251246A patent/IL251246A0/en unknown
- 2017-06-02 US US15/612,984 patent/US9889137B2/en active Active
-
2018
- 2018-01-08 US US15/864,994 patent/US10105369B2/en active Active
-
2020
- 2020-05-13 JP JP2020084527A patent/JP2020147571A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020147571A5 (enExample) | ||
| JP2021098740A5 (enExample) | ||
| JP2019513694A5 (enExample) | ||
| RU2451674C2 (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| JP2019142930A5 (enExample) | ||
| JP2016527279A5 (enExample) | ||
| Figlin et al. | Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors | |
| JP2020514311A5 (enExample) | ||
| US20240374571A1 (en) | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers | |
| Bauer et al. | Emerging agents for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors: current status and future directions | |
| JP2010510999A5 (enExample) | ||
| CN105848682A (zh) | 药物组合 | |
| JP2010501639A (ja) | 炎症性疾患の新規治療方法 | |
| JP2019510746A5 (enExample) | ||
| JP2004534010A5 (enExample) | ||
| JP2015503571A5 (enExample) | ||
| CN109715163A (zh) | 包含raf抑制剂和erk抑制剂的治疗组合 | |
| JP2018534288A5 (enExample) | ||
| JP2023175694A5 (enExample) | ||
| Kircher et al. | Targeting angiogenesis in colorectal cancer: tyrosine kinase inhibitors | |
| AU2014202963A1 (en) | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity | |
| JP2020518629A5 (enExample) | ||
| Zhong et al. | Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways | |
| JP2005527523A5 (enExample) | ||
| JP2025026846A5 (enExample) |